Meeting Agenda - HEALing Communities Study Design Workshop

Meeting Purpose

June 18, 2018

To bring together scientific experts, state partners, federal partners, and other key stakeholders to solicit feedback regarding important aspects of study design, infrastructure requirements, timelines, and budget allocation for a large multisite national research effort to develop and determine the impact of approaches for the systematic implementation and sustainability of an integrated set of evidence-based interventions within health care, behavioral health, justice systems, and community organizations to decrease opioid overdose deaths and events, lower incidence of opioid use disorders and hepatitis C, and increase the number of individuals who are receiving medication-assisted treatment and are retained in treatment beyond 6 months.

Meeting Format

Topics for feedback are divided into six sessions. Each session will begin with brief comments by two to three experts to kick off the discussion. Following their feedback, the session will open up and provide other participants the opportunity to provide comments and pose questions.


8:30 a.m.
Welcome and Self-Introductions
Nora D. Volkow, M.D., Director, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)

8:45 a.m.
Introductory Remarks
ADM Brett P. Giroir, M.D., Assistant Secretary for Health, Senior Advisor for Mental Health and Opioid Policy, U.S. Department of Health and Human Services

9:00 a.m.
The HEALing Communities Study: Overview and Vision
Nora D. Volkow, M.D., Director, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)

9:15 a.m.
Meeting Goals and Objectives
Redonna Chandler, Ph.D., Director, Office of AIDS Research, Scientific Director, HEALing Communities Study, NIDA, NIH
Christopher M. Jones, Pharm.D., M.P.H., Director, National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration (SAMHSA)

9:30 a.m.
Session 1: Study Design
Michael Dennis, Ph.D., Chestnut Health Systems
David M. Murray, Ph.D., Office of Disease Prevention, National Institutes of Health (NIH)
Holly Hagan, Ph.D., M.P.H., New York University Rory Meyers College of Nursing
Discussant: Lisa Marsch, Ph.D., Dartmouth College

11:00 a.m.
Session 2: Outcomes
Arthur Williams, M.D., M.B.E., Columbia University
Sharon L Walsh, Ph.D., University of Kentucky
Judith Feinberg, M.D., West Virginia University
Discussant: A. Thomas McLellan, Ph.D., Treatment Research Institute

12:15 p.m.

12:45 p.m.
Remarks from the Director of the National Institutes of Health
Francis S. Collins, M.D., Ph.D., Director, NIH

1:00 p.m.
Session 3: Opioid Prevention and Treatment Continuum
John Rotrosen, M.D., New York University School of Medicine
David Hawkins, Ph.D., University of Washington School of Social Work
Thomas D'Aunno, Ph.D., New York University
Discussant: A. Thomas McLellan, Ph.D., Treatment Research Institute

2:00 p.m.
Session 4: Health Economics Research
Bruce R. Schackman, Ph.D., M.B.A., Weill Cornell Medicine
A. David Paltiel, Ph.D., M.B.A., Yale School of Public Health
Discussant: Sarah Duffy, Ph.D., NIDA

2:45 p.m.
Session 5: Implementation Research
C. Hendricks Brown, Ph.D., Northwestern University
Mark McGovern, Ph.D., Stanford University
Todd Molfenter, Ph.D., University of Wisconsin–Madison
Discussant: Maureen Boyle, Ph.D., Addiction Policy Forum

3:45 p.m.
Session 6: Infrastructure, Partnerships, and Collaboration
Miriam Delphin-Rittmon, Ph.D., State of Connecticut
Rick Harwood, National Association of State Alcohol and Drug Abuse Directors
Faye Taxman, Ph.D., George Mason University
Discussant: Richard Sherman, Ph.D., Illinois Division of Substance Use Prevention and Recovery

4:45 p.m.
Wrap-up and Summary
Nora D. Volkow, M.D. and
Redonna Chandler, Ph.D., NIDA

5:00 p.m.